📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-11 17:07
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Span Divergent Q1 Results: Consolidated Revenue Drops 27% to ₹1.30 Cr; Swings to Net Loss
Span Divergent reported a weak Q1 FY27 (ending June 2026) with consolidated total income falling 27.3% YoY to ₹1.30 Cr from ₹1.79 Cr. The company posted a consolidated net loss of ₹10.96 Lakhs, a sharp reversal from the ₹14.50 Lakhs profit recorded in the same quarter last year. Standalone operations were particularly weak, with total income halving to ₹30.83 Lakhs. The company continues to struggle with loss-making subsidiaries, one of which has a negative net worth of ₹7.52 Cr.
Confidence: HIGH
What changedThe company has transitioned from a profitable Q1 in the previous year to a loss-making position, accompanied by a significant contraction in both standalone and consolidated revenues.
Why it mattersFor a micro-cap company with a ₹25 Cr market cap, persistent losses in subsidiaries and a 27% drop in quarterly revenue raise concerns about operational sustainability and the effectiveness of recent capital infusions.
Consolidated Revenue (Q1): ₹1.30 CrConsolidated Net Loss (Q1): ₹10.96 LakhsUnutilized Fundraise: ₹2.17 CrSubsidiary Negative Net Worth (Biospan): ₹7.52 CrRevenue vs TTM Revenue: 7.6%
📅 Short termThe stock is likely to face pressure in the short term due to the disappointing swing from profit to loss and the sharp decline in top-line growth.
📈 Long termThe long-term outlook remains high-risk given the substantial accumulated losses in subsidiaries and the recent significant reduction in promoter holding from 64% to 48%.
⚠ Risk flags
- Significant accumulated losses in subsidiaries (₹14.94 Cr in one unit)
- Negative net worth in Biospan Contamination Control subsidiary
- Sharp decline in promoter holding (down to 48.1% from 64%)
- Revenue contraction of 27% YoY
Key Highlights
Consolidated total income declined to ₹130.20 Lakhs from ₹179.21 Lakhs in the year-ago quarter.
Consolidated net loss stood at ₹10.96 Lakhs compared to a profit of ₹14.50 Lakhs in Q1 FY26.
Subsidiary Aranya Consulting and Biotech LLP reported accumulated losses of ₹14.94 Cr as of March 31, 2026.
Biospan Contamination Control Solutions Pvt Ltd has a negative net worth, with liabilities exceeding assets by ₹7.52 Cr.
Unutilized proceeds from the October 2025 preferential issue stand at ₹217.06 Lakhs out of ₹579.30 Lakhs raised.
👀 What to Watch
Investors should monitor the utilization of the remaining ₹2.17 Cr in preferential funds and watch for any concrete turnaround signs in the Biospan and Aranya subsidiaries, which are currently weighing down the consolidated balance sheet.
Span Divergent Q1 FY27: Consolidated Loss Widens to ₹1.15 Cr; Revenue Declines to ₹1.30 Cr
Span Divergent reported a weak Q1 FY27 with consolidated total income falling to ₹1.30 Cr from ₹1.79 Cr in the year-ago period. The consolidated loss before tax widened significantly to ₹1.15 Cr, compared to a loss of ₹0.33 Cr in Q1 FY26. The company's financial health is under pressure from its subsidiaries, particularly Biospan Contamination Control, which has a negative net worth of ₹7.52 Cr. Furthermore, ₹2.11 Cr remains unutilized from the ₹5.79 Cr preferential issue raised in October 2025, intended for inventory and operational ramp-up.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results, showing a widening of losses and a decline in revenue, alongside detailed disclosures of severe financial stress in its subsidiary units.
Why it mattersWith a market cap of only ₹25 Cr and TTM losses of ₹3 Cr, the continued erosion of net worth in subsidiaries and widening quarterly losses pose a significant risk to the company's going-concern status and valuation.
Consolidated Revenue (Q1 FY27): ₹1.30 CrConsolidated Loss Before Tax (Q1 FY27): ₹1.15 CrUnutilized Preferential Funds: ₹2.11 CrSubsidiary Negative Net Worth (Biospan): ₹7.52 CrQ1 Revenue vs TTM Revenue: ~7.6%
📅 Short termThe stock is likely to face downward pressure due to the widening losses and the disclosure of significant accumulated losses in subsidiaries.
📈 Long termThe long-term outlook is highly uncertain given the negative ROCE (-30%) and the substantial erosion of net worth in key subsidiary LLPs; a structural turnaround is required.
⚠ Risk flags
- Significant subsidiary losses
- Negative net worth in key business units
- Widening consolidated losses
- High operating expenses relative to revenue
Key Highlights
Consolidated total income decreased by 27% YoY to ₹1.30 Cr in Q1 FY27.
Consolidated loss before tax widened to ₹1.15 Cr from ₹0.33 Cr in the previous year's corresponding quarter.
Subsidiary Biospan Contamination Control Solutions Pvt Ltd reports a negative net worth of ₹7.52 Cr with liabilities exceeding assets.
Aranya Consulting and Biotech LLP subsidiary has accumulated losses totaling ₹14.94 Cr as of March 31, 2026.
₹2.11 Cr of the ₹5.79 Cr raised via preferential issue on October 15, 2025, remains unutilized.
👀 What to Watch
Investors should monitor the utilization of the remaining ₹2.11 Cr in preferential funds and the management's progress in reviving the loss-making subsidiaries, which are currently a significant drag on the consolidated balance sheet.
